Before transitioning to the pharmaceutical industry sector, Dr. Kang spent over two decades researching molecular biology at top academic institutes. She holds an extensive track record in executive biotech leadership, successfully spearheading major cross-border R&D transactions and M&A activities. She is dedicated to improving the biology research process with cutting-edge AI agents; made by biologists, for biologiests.